Please login to the form below

Not currently logged in
Email:
Password:

Tonix names chief medical officer

Gregory Sullivan is experience academic in psychiatry

The clinical-stage specialty pharma company Tonix Pharmaceuticals has named Dr Gregory Sullivan as its first chief medical officer.

Dr Sullivan, an experienced psychiatrist and researcher, will oversee medical aspects of the New York headquartered company's clinical research and development programme, which is focused on developing treatments for diseases of the central nervous system.

It is the second senior clinical appointment that Tonix has made this year following the hire of Dr Donald Kellerman as senior VP, clinical development and regulatory affairs.

Tonix is bulking up its research team as it anticipates the first trial involving lead candidate TNX-102 SL in fibromyalgia. The drug is also in a more advanced stage of research for post-traumatic stress disorder (PTSD).

Dr Sullivan has enjoyed an extensive clinical career including experience as an assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University Medical Center, a research scientist at the New York State Psychiatric Institute (NYSPI), and as a practicing psychiatrist.

His expertise includes PTSD and has been involved in several studies into the condition. He has also served on the scientific advisory board at Tonix since 2010.

"It is my hope that my medical expertise and scientific background will contribute to the successful development of this promising pipeline of novel therapeutic candidates to bring much needed treatment options to patients suffering with these challenging conditions,” said Dr Sullivan.

4th June 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics